Hemofilter with Adsorptive Capacities: Case Report Series.

Area of Science:

• Critical Care Medicine
• Nephrology
• Biomaterials

Background:

• Sepsis-associated acute kidney injury (AKI) presents a significant clinical challenge.
• oXiris is a novel blood purification system designed to address systemic inflammation in sepsis.
• Its capabilities include cytokine and endotoxin adsorption, alongside renal support.

Observation:

• This study presents four case reports of septic AKI patients treated with oXiris in Chinese intensive care units.
• Expert insights on practical application and optimal timing of oXiris therapy were incorporated.
• Patient characteristics influencing treatment response were investigated.

Findings:

• Early initiation of oXiris as an adjuvant therapy, alongside effective infection source control, is recommended.
• oXiris can be safely used in patients at high risk of bleeding for up to 36 hours without anticoagulation.
• No significant adverse effects on serum protein levels or platelet counts were observed.

Implications:

• oXiris may offer a valuable therapeutic option for managing systemic inflammation in septic AKI.
• Clinical judgment is crucial for determining the optimal initiation and discontinuation of oXiris therapy in the absence of definitive biomarkers.
• Further research is warranted to establish optimal treatment protocols and long-term outcomes.